Compare · MRK vs XERS
MRK vs XERS
Side-by-side comparison of Merck & Company Inc. (MRK) and Xeris Biopharma Holdings Inc. (XERS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and XERS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $329.65B, about 106.3x XERS ($3.10B).
- MRK has been more active in the news (25 items in the past 4 weeks vs 12 for XERS).
- MRK has more recent analyst coverage (25 ratings vs 12 for XERS).
- Company
- Merck & Company Inc.
- Xeris Biopharma Holdings Inc.
- Price
- $133.70+0.73%
- -
- Market cap
- $329.65B
- $3.10B
- 1M return
- -9.16%
- -
- 1Y return
- +36.81%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 25
- 12
- Recent ratings
- 25
- 12
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Xeris Biopharma Holdings Inc.
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.
Latest MRK
- Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma
- Merck and Isomorphic Labs Enter Strategic Research Collaboration
- Merck & Company Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director
- Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
- Merck Announces First-Quarter 2027 Dividend
- EVP&Pres, Merck Animal Heallth Deluca Richard R. exercised 58,185 shares at a strike of $77.62 and sold $8,611,875 worth of shares (58,185 units at $148.01), decreasing direct ownership by 0.00% to 112,955 units (SEC Form 4)
- SEC Form 13F-HR filed by Merck & Company Inc.
- Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
- Merck to Participate in the Jefferies Global Healthcare Conference in London
Latest XERS
- Officer Mcculloch Kevin sold $312,215 worth of shares (25,000 units at $12.49) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,559,208 units (SEC Form 4)
- SEC Form 10-Q filed by Xeris Biopharma Holdings Inc.
- Xeris Biopharma Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
- Officer Pieper Steven sold $51,174 worth of shares (5,000 units at $10.23) as part of a pre-agreed trading plan, decreasing direct ownership by 0.37% to 1,346,053 units (SEC Form 4)
- Officer Hecht Beth sold $255,828 worth of shares (25,000 units at $10.23) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,086,130 units (SEC Form 4)
- Officer Mcculloch Kevin sold $153,488 worth of shares (15,000 units at $10.23) as part of a pre-agreed trading plan, decreasing direct ownership by 0.94% to 1,584,208 units (SEC Form 4)
- Director Taddese Menassie was granted 22,365 shares (SEC Form 4)
- SEC Form 3 filed by new insider Taddese Menassie
- SEC Form 144 filed by Xeris Biopharma Holdings Inc.